ASX:CYCCyclopharm Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cyclopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$1.36 -0.01 (-0.73 %) (As of 05/13/2020) Add Compare Share Today's RangeA$1.36Now: A$1.36▼A$1.3650-Day Range N/A52-Week RangeA$0.70Now: A$1.36▼A$1.73Volume10,000 shsAverage VolumeN/AMarket Capitalization$107.79 millionP/E RatioN/ADividend Yield0.64%BetaN/A ProfileAdvanced ChartCompetitorsDividendInsider TradesHeadlines Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The company offers diagnostic equipment and consumables, which are used by physicians in the detection of pulmonary embolism. It also provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases; and Ultralute, a patented nuclear medicine technology for use in Mollybdenum-99 generators. The company serves nuclear medicine departments in hospitals and clinics. Cyclopharm Limited is headquartered in Kingsgrove, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cyclopharm. Previous Next 2.3 Community Rank Outperform VotesCyclopharm has received 10 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCyclopharm has received 12 “underperform” votes. (Add your “underperform” vote.)Community SentimentCyclopharm has received 54.55% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cyclopharm and other stocks. Vote “Outperform” if you believe CYC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 1.7 Dividend Strength Dividend LeadershipCyclopharm is a leading dividend payer. It pays a dividend yield of 0.64%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthCyclopharm does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclopharm insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$16,000.00 in company stock and sold A$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclopharm is -31.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclopharm is -31.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclopharm has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolASX:CYC Previous Symbol CUSIPN/A CIKN/A Webwww.cyclopharm.com.au Phone61 2 9541 0411Debt Debt-to-Equity Ratio21.21 Current Ratio5.64 Quick Ratio4.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.01 million Price / Sales6.34 Cash FlowA$0.16 per share Price / Cash Flow8.40 Book ValueA$0.30 per share Price / Book4.58Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares79,259,000Market Cap$107.79 million Next Earnings DateN/A OptionableNot Optionable Receive CYC News and Ratings via Email Sign-up to receive the latest news and ratings for CYC and its competitors with MarketBeat's FREE daily newsletter. Cyclopharm (ASX:CYC) Frequently Asked Questions How often does Cyclopharm pay dividends? What is the dividend yield for Cyclopharm? Cyclopharm announced a Final dividend on Thursday, February 27th. Stockholders of record on Tuesday, April 7th will be given a dividend of 0.005 per share on Tuesday, April 7th. This represents a dividend yield of 0.52%. The ex-dividend date of this dividend is Monday, March 30th. View Cyclopharm's dividend history. Has Cyclopharm been receiving favorable news coverage? Media coverage about CYC stock has been trending negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cyclopharm earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCyclopharm. Who are some of Cyclopharm's key competitors? Some companies that are related to Cyclopharm include Avacta Group (AVCT), Creo Medical Group (CREO), Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Patient Home Monitoring (PTQ), Advanced Oncotherapy (AVO), Somnomed (SOM), Resonance Health (RHT), Kromek Group (KMK), REVA Medical (RVA), Total Brain (TTB) and EMvision Medical Devices (EMV). View all competitors. Who are Cyclopharm's key executives? Cyclopharm's management team includes the following people: Mr. James S. McBrayer, CEO, MD, Company Sec. & Director (Age 54)Mr. Mathew Farag, Chief Operating OfficerMr. Graham N. Phillips, Fin. Mang.Ms. Sui Ling Cheah, Financial Controller (Age 49)Mr. Lynn McLauchlin, Gen. Mang. of Canada What is Cyclopharm's stock symbol? Cyclopharm trades on the ASX under the ticker symbol "CYC." What is Cyclopharm's stock price today? One share of CYC stock can currently be purchased for approximately A$1.36. How big of a company is Cyclopharm? Cyclopharm has a market capitalization of $107.79 million and generates $17.01 million in revenue each year. What is Cyclopharm's official website? The official website for Cyclopharm is www.cyclopharm.com.au. How can I contact Cyclopharm? The company can be reached via phone at 61 2 9541 0411. This page was last updated on 6/1/2020 by MarketBeat.com Staff
